# A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

> **NCT03553563** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 50 (actual)

## Conditions studied

- Reflux Esophagitis
- Gastric Ulcer
- Duodenal Ulcer

## Interventions

- **DRUG:** D961H capsule 10mg
- **DRUG:** D961H sachet 10mg

## Key facts

- **NCT ID:** NCT03553563
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-24
- **Primary completion:** 2022-12-27
- **Final completion:** 2022-12-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553563, "A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03553563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*